Research Article 
Greater regional brain atrophy rate in healthy elderly subjects with a history of cigarette smoking
Timothy C. Durazzo, Philip S. Insel and Michael W. Weiner
Alzheimer`s & Dementia, 2012, 8(6), 513-519. DOI: 10.1016/j.jalz.2011.10.006
Abstract
Background Little is known about the effects of cigarette smoking on longitudinal brain morphological changes in the elderly. This study investigated the effects of a history of cigarette smoking on changes in regional brain volumes over 2 years in healthy, cognitively intact elderly individuals. We predicted that individuals with a history of cigarette smoking, compared with never smokers, demonstrate greater rate of atrophy over 2 years in regions that manifest morphological abnormalities in the early stages of Alzheimer‘s disease (AD), as well as in the extended brain reward/executive oversight system (BREOS), which is implicated in the development and maintenance of substance use disorders. Methods Participants were healthy, cognitively normal elderly control subjects (75.9 ± 4.8 years of age) with any lifetime history of cigarette smoking (n = 68) or no history of smoking (n = 118). Data were obtained through the Alzheimer Disease Neuroimaging Initiative from 2005 to 2010. Participants completed four magnetic resonance scans over 2 years. A standardized protocol using high-resolution three-dimensional T1-weighted sequences at 1.5 T was used for structural imaging and regional brain volumetric analyses. Results Smokers demonstrated a significantly greater atrophy rate over 2 years than nonsmokers in multiple brain regions associated with the early stages of AD, as well as in the BREOS system. Groups did not differ on the rate of global cortical atrophy. Conclusions A history of cigarette smoking in this healthy elderly cohort was associated with decreased structural integrity of multiple brain regions, which manifested as a greater rate of atrophy over 2 years in regions specifically affected by incipient AD as well as chronic substance abuse.
ASCI-ID: 285-224
Similar Articles
A European perspective on population studies of dementia
Alzheimer`s & Dementia, 2011, 7(1), 3-9. DOI: 10.1016/j.jalz.2010.12.003
Operationalizing diagnostic criteria for Alzheimer‘s disease and other age-related cognitive impairment–Part 2Alzheimer`s & Dementia, 2011, 7(1), 35-52. DOI: 10.1016/j.jalz.2010.12.002
Sources of variability in estimates of the prevalence of Alzheimer‘s disease in the United StatesAlzheimer`s & Dementia, 2011, 7(1), 74-79. DOI: 10.1016/j.jalz.2010.11.006
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloidAlzheimer`s & Dementia, 2011, 7(2), 133-141. DOI: 10.1016/j.jalz.2010.08.230
Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer`s & Dementia, 2011, 7(3), 257-262. DOI: 10.1016/j.jalz.2011.03.004
The Alzheimer‘s Association external quality control program for cerebrospinal fluid biomarkersAlzheimer`s & Dementia, 2011, 7(4), 386-395. DOI: 10.1016/j.jalz.2011.05.2243
Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer‘s disease study cohorts from phase 3 trials of semagacestat and solanezumabAlzheimer`s & Dementia, 2011, 7(4), 396-401. DOI: 10.1016/j.jalz.2011.05.2353
Extended results of the Alzheimer‘s disease anti-inflammatory prevention trialAlzheimer`s & Dementia, 2011, 7(4), 402-411. DOI: 10.1016/j.jalz.2010.12.014
Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer‘s diseaseAlzheimer`s & Dementia, 2011, 7(4), 425-435. DOI: 10.1016/j.jalz.2010.09.003
Intracranial atherosclerosis as a contributing factor to Alzheimer‘s disease dementiaAlzheimer`s & Dementia, 2011, 7(4), 436-444. DOI: 10.1016/j.jalz.2010.08.228
Transcranial Doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2011, 7(4), 445-455. DOI: 10.1016/j.jalz.2010.09.002
The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ɛ3/ɛ3 genotypeAlzheimer`s & Dementia, 2011, 7(4), 456-465. DOI: 10.1016/j.jalz.2010.11.012
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2011, 7(4), 474-485. DOI: 10.1016/j.jalz.2011.04.007
Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimer‘s disease patientsAlzheimer`s & Dementia, 2011, 7(5), 493-500. DOI: 10.1016/j.jalz.2011.01.004
Frequency of Alzheimer‘s disease pathology at autopsy in patients with clinical normal pressure hydrocephalusAlzheimer`s & Dementia, 2011, 7(5), 509-513. DOI: 10.1016/j.jalz.2010.12.008
Long-term progression of Alzheimer‘s disease in patients under antidementia drugsAlzheimer`s & Dementia, 2011, 7(6), 579-592. DOI: 10.1016/j.jalz.2011.02.009
The measurement of everyday cognition: Development and validation of a short form of the Everyday Cognition scalesAlzheimer`s & Dementia, 2011, 7(6), 593-601. DOI: 10.1016/j.jalz.2011.02.007
Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer‘s disease trialsAlzheimer`s & Dementia, 2011, 7(6), 602-610. DOI: 10.1016/j.jalz.2011.01.005
An economic evaluation of early assessment for Alzheimer‘s disease in the United KingdomAlzheimer`s & Dementia, 2012, 8(1), 22-30. DOI: 10.1016/j.jalz.2010.07.001
Modeling Alzheimer‘s disease progression using the disease system analysis approachAlzheimer`s & Dementia, 2012, 8(1), 39-50. DOI: 10.1016/j.jalz.2010.12.012
Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's diseaseAlzheimer`s & Dementia, 2012, 8(1), 51-59. DOI: 10.1016/j.jalz.2011.06.003
Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization InitiativeAlzheimer`s & Dementia, 2012, 8(1), 65-73. DOI: 10.1016/j.jalz.2011.07.004
[123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodiesAlzheimer`s & Dementia, 2012, 8(1), 74-83. DOI: 10.1016/j.jalz.2011.08.003
An investigation of PreMCI: Subtypes and longitudinal outcomesAlzheimer`s & Dementia, 2012, 8(3), 172-179. DOI: 10.1016/j.jalz.2011.03.002
Serum antibodies to periodontal pathogens are a risk factor for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(3), 196-203. DOI: 10.1016/j.jalz.2011.04.006
Cognitive and structural magnetic resonance imaging features of Lewy body dementia and Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(3), 211-218. DOI: 10.1016/j.jalz.2011.04.008
Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(3), 219-226. DOI: 10.1016/j.jalz.2011.03.012
Alzheimer‘s disease: Pathogenesis and preventionAlzheimer`s & Dementia, 2012, 8(3), 227-233. DOI: 10.1016/j.jalz.2012.01.011
The epidemiology of Alzheimer‘s disease: Laying the foundation for drug design, conduct, and analysis of clinical trialsAlzheimer`s & Dementia, 2012, 8(3), 237-242. DOI: 10.1016/j.jalz.2011.12.005
Safety and biomarker effects of solanezumab in patients with Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(4), 261-271. DOI: 10.1016/j.jalz.2011.09.224
Leptin and dementia over 32 years–The Prospective Population Study of WomenAlzheimer`s & Dementia, 2012, 8(4), 272-277. DOI: 10.1016/j.jalz.2011.05.2411
Gaining precision on the Alzheimer‘s Disease Assessment Scale-cognitive: A comparison of item response theory-based scores and total scoresAlzheimer`s & Dementia, 2012, 8(4), 288-294. DOI: 10.1016/j.jalz.2011.05.2409
Effect of human cerebrospinal fluid sampling frequency on amyloid-β levelsAlzheimer`s & Dementia, 2012, 8(4), 295-303. DOI: 10.1016/j.jalz.2011.05.900
Worldwide Alzheimer‘s Disease Neuroimaging InitiativeAlzheimer`s & Dementia, 2012, 8(4), 337-342. DOI: 10.1016/j.jalz.2012.04.007
Some evolutionary perspectives on Alzheimer‘s disease pathogenesis and pathologyAlzheimer`s & Dementia, 2012, 8(4), 343-351. DOI: 10.1016/j.jalz.2011.05.2408
Cardiovascular fitness is associated with altered cortical glucose metabolism during working memory in ɛ4 carriersAlzheimer`s & Dementia, 2012, 8(4), 352-356. DOI: 10.1016/j.jalz.2011.04.010
Common Alzheimer‘s Disease Research Ontology: National Institute on Aging and Alzheimer‘s Association Collaborative ProjectAlzheimer`s & Dementia, 2012, 8(4), 372-375. DOI: 10.1016/j.jalz.2012.05.2115
A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in agingAlzheimer`s & Dementia, 2012, 8(5), 381-388. DOI: 10.1016/j.jalz.2011.10.005
Amyloid imaging in dementias with atypical presentationAlzheimer`s & Dementia, 2012, 8(5), 389-398. DOI: 10.1016/j.jalz.2011.07.003
Comparing new templates and atlas-based segmentations in the volumetric analysis of brain magnetic resonance images for diagnosing Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(5), 399-406. DOI: 10.1016/j.jalz.2011.07.002
Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studiesAlzheimer`s & Dementia, 2012, 8(5), 407-416. DOI: 10.1016/j.jalz.2011.05.2413
Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound BAlzheimer`s & Dementia, 2012, 8(6), 496-501. DOI: mailto:[email protected]
Differential prediction of vascular dementia and Alzheimer‘s disease in nondemented older adults within 5 years of initial testingAlzheimer`s & Dementia, 2012, 8(6), 528-535. DOI: 10.1016/j.jalz.2011.09.233
A new informant-based questionnaire for instrumental activities of daily living in dementiaAlzheimer`s & Dementia, 2012, 8(6), 536-543. DOI: 10.1016/j.jalz.2011.08.006
Comparison of International Working Group criteria and National Institute on Aging–Alzheimer‘s Association criteria for Alzheimer‘s diseaseAlzheimer`s & Dementia, 2012, 8(6), 560-563. DOI: 10.1016/j.jalz.2011.10.008
Association of environmental tobacco smoke with dementia and Alzheimer‘s disease among never smokersAlzheimer`s & Dementia, 2012, 8(6), 590-595. DOI: 10.1016/j.jalz.2011.09.231
The worldwide economic impact of dementia 2010Alzheimer`s & Dementia, 2013, 9(1), 1-11. DOI: 10.1016/j.jalz.2012.11.006
Apolipoprotein E genotype, dementia, and mortality in the oldest old: The 90+ StudyAlzheimer`s & Dementia, 2013, 9(1), 12-18. DOI: 10.1016/j.jalz.2011.12.004
Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer‘s disease and related disordersAlzheimer`s & Dementia, 2013, 9(1), 30-38. DOI: 10.1016/j.jalz.2012.11.002
The economics of mild cognitive impairmentAlzheimer`s & Dementia, 2013, 9(1), 58-62. DOI: 10.1016/j.jalz.2012.05.2117
Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on AgingAlzheimer`s & Dementia, 2013, 9(2), 113-122. DOI: 10.1016/j.jalz.2011.09.223
Intracerebral propagation of Alzheimer‘s disease: Strengthening evidence of a herpes simplex virus etiologyAlzheimer`s & Dementia, 2013, 9(2), 169-175. DOI: 10.1016/j.jalz.2012.07.005
Phenotypic regional functional imaging patterns during memory encoding in mild cognitive impairment and Alzheimer's diseaseAlzheimer`s & Dementia, 2013, 9(3), 284-294. DOI: 10.1016/j.jalz.2011.12.006
Effectiveness of antidementia drugs in delaying Alzheimer's disease progressionAlzheimer`s & Dementia, 2013, 9(3), 338-345. DOI: 10.1016/j.jalz.2012.01.002
Risk disclosure and preclinical Alzheimer‘s disease clinical trial enrollmentAlzheimer`s & Dementia, 2013, 9(3), 356-359. DOI: 10.1016/j.jalz.2012.03.001
β-Site amyloid precursor protein–cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tauAlzheimer`s & Dementia, 2013, 9(4), 386-391. DOI: 10.1016/j.jalz.2012.01.015
Cerebral atrophy, apolipoprotein E ε4, and rate of decline in everyday function among patients with amnestic mild cognitive impairmentAlzheimer`s & Dementia, 2010, 6(5), 404-411. DOI: 10.1016/j.jalz.2010.02.003
Homocysteine, progression of ventricular enlargement, and cognitive decline: The Second Manifestations of ARTerial disease–Magnetic Resonance studyAlzheimer`s & Dementia, 2013, 9(3), 302-309. DOI: 10.1016/j.jalz.2011.11.008
White matter is altered with parental family history of Alzheimer’s diseaseAlzheimer`s & Dementia, 2010, 6(5), 394-403. DOI: 10.1016/j.jalz.2009.11.003
White matter is altered with parental family history of Alzheimer’s diseaseAlzheimer`s & Dementia, 2010, 6(5), 394-403. DOI: 10.1016/j.jalz.2009.11.003
Cerebral atrophy, apolipoprotein E ε4, and rate of decline in everyday function among patients with amnestic mild cognitive impairmentAlzheimer`s & Dementia, 2010, 6(5), 404-411. DOI: 10.1016/j.jalz.2010.02.003
The Alzheimer’s Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomesAlzheimer`s & Dementia, 2010, 6(3), 257-264. DOI: 10.1016/j.jalz.2010.03.002
The Alzheimer’s Disease Neuroimaging Initiative: Progress report and future plansAlzheimer`s & Dementia, 2010, 6(3), 202-211. DOI: 10.1016/j.jalz.2010.03.007
The Alzheimer’s Disease Neuroimaging Initiative: Perspectives of the Industry Scientific Advisory BoardAlzheimer`s & Dementia, 2010, 6(3), 286-290. DOI: 10.1016/j.jalz.2010.03.010
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer‘s Association Research Roundtable WorkgroupAlzheimer`s & Dementia, 2011, 7(4), 367-385. DOI: 10.1016/j.jalz.2011.05.2351
Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimer‘s disease patientsAlzheimer`s & Dementia, 2011, 7(5), 493-500. DOI: 10.1016/j.jalz.2011.01.004
Impact of apolipoprotein ɛ4–cerebrospinal fluid beta-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairmentAlzheimer`s & Dementia, 2011, 7(5), 514-520. DOI: 10.1016/j.jalz.2010.12.010
Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's diseaseAlzheimer`s & Dementia, 2012, 8(1), 51-59. DOI: 10.1016/j.jalz.2011.06.003
An investigation of PreMCI: Subtypes and longitudinal outcomesAlzheimer`s & Dementia, 2012, 8(3), 172-179. DOI: 10.1016/j.jalz.2011.03.002
Vascular risk factors, apolipoprotein E, and hippocampal decline on magnetic resonance imaging over a 10-year follow-upAlzheimer`s & Dementia, 2012, 8(5), 417-425. DOI: 10.1016/j.jalz.2011.07.005
Decreased gray matter diffusivity: A potential early Alzheimer‘s disease biomarker?Alzheimer`s & Dementia, 2013, 9(1), 93-97. DOI: 10.1016/j.jalz.2011.11.004
Amyloid positron emission tomography with 18F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer‘s diseaseAlzheimer`s & Dementia, 2013, 9(3), 295-301. DOI: 10.1016/j.jalz.2012.01.006